CULLINAN THERAPEUTICS, INC.: total assets
Total assets for CULLINAN THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CULLINAN THERAPEUTICS, INC. financial histories
What this measure means
Resources recognized on the balance sheet. Book assets are not the market value of the business.
Exact concept: us-gaap:Assets. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 448,374,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099362 |
| At date | 2024-12-31 | 621,824,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099362 |
| At date | 2023-12-31 | 484,182,000 | USD | 2025-02-27 | 10-K · 0000950170-25-028346 |
| At date | 2022-12-31 | 561,117,000 | USD | 2024-03-14 | 10-K · 0000950170-24-031143 |
| At date | 2021-12-31 | 437,185,000 | USD | 2023-03-09 | 10-K · 0000950170-23-006839 |
| At date | 2020-12-31 | 214,708,000 | USD | 2022-03-17 | 10-K · 0000950170-22-004002 |
Related financial histories
- CULLINAN THERAPEUTICS, INC.: total liabilities
- CULLINAN THERAPEUTICS, INC.: stockholders equity
- CULLINAN THERAPEUTICS, INC.: cash and cash equivalents
- CULLINAN THERAPEUTICS, INC.: net income or loss
- CULLINAN THERAPEUTICS, INC.: operating cash flow
- CULLINAN THERAPEUTICS, INC.: capital expenditure payments
- CULLINAN THERAPEUTICS, INC.: contract revenue excluding tax
- CULLINAN THERAPEUTICS, INC.: financing cash flow
- CULLINAN THERAPEUTICS, INC.: investing cash flow
- CULLINAN THERAPEUTICS, INC.: retained earnings or deficit
- CULLINAN THERAPEUTICS, INC.: basic weighted-average shares
- CULLINAN THERAPEUTICS, INC.: diluted weighted-average shares
- CULLINAN THERAPEUTICS, INC.: basic earnings per share
- CULLINAN THERAPEUTICS, INC.: diluted earnings per share
- CULLINAN THERAPEUTICS, INC.: income tax expense or benefit
- CULLINAN THERAPEUTICS, INC.: net property, plant and equipment
- CULLINAN THERAPEUTICS, INC.: share-based compensation expense
- CULLINAN THERAPEUTICS, INC.: operating income or loss
- CULLINAN THERAPEUTICS, INC.: current assets
- CULLINAN THERAPEUTICS, INC.: current liabilities
- CULLINAN THERAPEUTICS, INC.: current accounts payable
- CULLINAN THERAPEUTICS, INC.: operating expenses
- CULLINAN THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- CULLINAN THERAPEUTICS, INC. / CIK 0001789972
- Captured
- 2026-09-21T17:27:31.629Z
- SEC response SHA-256
b27fca20bc22c828a65d8527782bea255b37a5346a489a029a3dfe906e83bfd0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001789972.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))